Back

Characterization of cardiovascular risk profile and therapeutic management in patients with type 2 diabetes mellitus: insight from the CardioMET Italian registry

31 August 2026 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Therapeutic advancements in type 2 diabetes mellitus Antidiabetic Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Federica Marzano

University of Naples Federico II, Naples (Italy)

3 More presentations in this session

Presentation thumbnail
Utilization patterns of potent GLP-1-RA among patients with type 2 diabetes in clinical practice
Ms S. Matseyko (DE)
Abstract
Presentation thumbnail
Cardiovascular effects of tirzepatide in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
Professor M. Saffi (Porto Alegre, BR)
Abstract
Presentation thumbnail
Effect of glucagon-like peptide-1 receptor agonists on nonfatal cardiovascular events in patients with type 2 diabetes and high cardiovascular risk
Doctor K. Abraham (Staten Island, US)
Abstract

Access the full session

Session thumbnail
Therapeutic advancements in type 2 diabetes mellitus

The Event

Event poster

ESC Congress 2026

31 August 2026 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Novel multidisciplinary cardiometabolic clinic in a UK tertiary cardiology centre: early activity, interventions and potential for cardiovascular risk optimisation
27 August 2021
thumbnail
Congress Presentation
Secondary prevention of coronary artery disease: a retrospective observational analysis of italian healthcare administrative data
7 April 2022
thumbnail
Congress Presentation
Real world risk of major outcomes for type 2 diabetes with stable coronary artery disease without prior MI or stroke and THEMIS-like patients using the SNDS French nationwide claims database
30 August 2020
thumbnail
Congress Presentation
Guideline-directed medical therapy patterns in heart failure with reduced ejection fraction: the OPTIMA-HF registry
31 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources